TY - JOUR
T1 - MYC in pancreatic cancer
T2 - Novel mechanistic insights and their translation into therapeutic strategies
AU - Hessmann, E.
AU - Schneider, G.
AU - Ellenrieder, V.
AU - Siveke, J. T.
N1 - Publisher Copyright:
© 2016 Macmillan Publishers Limited.
PY - 2016/3/31
Y1 - 2016/3/31
N2 - Owing to its aggressiveness, late detection and marginal therapeutic accessibility, pancreatic ductal adenocarcinoma (PDAC) remains a most challenging malignant disease. Despite scientific progress in the understanding of the mechanisms that underly PDAC initiation and progression, the successful translation of experimental findings into effective new therapeutic strategies remains a largely unmet need. The oncogene MYC is activated in many PDAC cases and is a master regulator of vital cellular processes. Excellent recent studies have shed new light on the tremendous functions of MYC in cancer and identified inhibition of MYC as a likewise beneficial and demanding effort. This review will focus on mechanisms that contribute to deregulation of MYC expression in pancreatic carcinogenesis and progression and will summarize novel biological findings from recent in vivo models. Finally, we provide a perspective, how regulation of MYC in PDAC may contribute to the development of new therapeutic approaches.
AB - Owing to its aggressiveness, late detection and marginal therapeutic accessibility, pancreatic ductal adenocarcinoma (PDAC) remains a most challenging malignant disease. Despite scientific progress in the understanding of the mechanisms that underly PDAC initiation and progression, the successful translation of experimental findings into effective new therapeutic strategies remains a largely unmet need. The oncogene MYC is activated in many PDAC cases and is a master regulator of vital cellular processes. Excellent recent studies have shed new light on the tremendous functions of MYC in cancer and identified inhibition of MYC as a likewise beneficial and demanding effort. This review will focus on mechanisms that contribute to deregulation of MYC expression in pancreatic carcinogenesis and progression and will summarize novel biological findings from recent in vivo models. Finally, we provide a perspective, how regulation of MYC in PDAC may contribute to the development of new therapeutic approaches.
UR - http://www.scopus.com/inward/record.url?scp=84933576541&partnerID=8YFLogxK
U2 - 10.1038/onc.2015.216
DO - 10.1038/onc.2015.216
M3 - Review article
C2 - 26119937
AN - SCOPUS:84933576541
SN - 0950-9232
VL - 35
SP - 1609
EP - 1618
JO - Oncogene
JF - Oncogene
IS - 13
ER -
